Korro Bio (KRRO) Other Operating Expenses (2018 - 2025)

Korro Bio (KRRO) posted Other Operating Expenses of $34.5 million for Q4 2025, down 36.96% on a QoQ basis from $54.8 million in Q4 2023.

Korro Bio (KRRO) Other Operating Expenses (2018 - 2025) Analysis & Trends

Korro Bio's Other Operating Expenses history runs 5 years deep, the most recent figure standing at $34.5 million for Q4 2025.

Quarterly Other Operating Expenses changed N/A year-over-year to $34.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $34.5 million (changed N/A YoY) and the FY2025 annual result came in at $30.9 million, changed N/A from the prior year.
Other Operating Expenses was $34.5 million for Q4 2025 at Korro Bio, down from $54.8 million in the prior quarter.
Across five years, Other Operating Expenses topped out at $54.8 million in Q4 2023 and bottomed at $34.5 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,981.90 Bn	66,981.62 Bn	-
2	Nanobiotix	1,913.50 Bn	1,913.44 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.03 Bn	467.24 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.09 Bn	114.84 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.01 Bn	61.26 Bn	3.31 Bn
7	Belite Bio	62.34 Bn	62.34 Bn	-
8	Argenx Se	55.99 Bn	50.80 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn
10	Korro Bio	122.37 Mn	8.40 Mn	-

Download Data